Drugmaker Wockhardt said that the United States Food and Drug Administration (US FDA) had accepted the New Drug Application ...

Wockhardt today announced that the United States Food and Drug Administration (US FDA) has formally accepted the New Drug Application (NDA) for its novel, first-in-class antibiotic Zaynich. The NDA ...

Zaynich is Wockhardt's novel antibiotic candidate aimed at tackling resistant bacterial infections, an area where global ...

Outliers 2025 by Outlook Business reveals how Wockhardt’s $700M push into antibiotic innovation is paying off, with Zaynich ...

Wockhardt zoomed 18.01% to Rs 1455.70 after the company said that the United States Food and Drug Administration (US FDA) has formally accepted the new drug application (NDA) for its novel, ...

Wockhardt's shares jumped 19.3% to ₹1,473 following the US FDA's acceptance of its antibiotic drug Zaynich's New Drug ...

Mumbai: Wockhardt Ltd. has announced that the United States Food and Drug Administration (US FDA) has formally accepted the ...

The US FDA has accepted Wockhardt’s New Drug Application for Zaynich, its first-in-class antibiotic. This marks the ...

Wockhardt receives NDA status from US FDA for its novel antibiotic Zaynich, a first for an Indian pharma company. Shares ...

Khorakiwala said the Mumbai-based drugmaker is already laying groundwork for commercialization, with options ranging from ...

Wockhardt shares were trading 18.31% higher at Rs 1459.4 per share on BSE with a market capitalisation of Rs 23,713.14 crore ...